公开(公告)号：US20240336701A1

公开(公告)日：2024-10-10

申请号：US18427264

申请日：2024-01-30

Applicant: Novartis AG

Inventor： Michael DIDONATO ,  Christoph ERKEL ,  Anna Galkin ,  Scott Martin GLASER ,  Klaus Felix HARTLEPP ,  Yong JIA ,  Alexandra KRAUS ,  Christian Cho-Hua LEE ,  Sarah Michelle RUE ,  Jian SHI ,  Xenia Karola WEZLER

IPC: C07K16/40 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K16/40 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/92

Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.

公开(公告)号：US20210100812A1

公开(公告)日：2021-04-08

申请号：US17108728

申请日：2020-12-01

Applicant: NOVARTIS AG

Inventor： NgocDiep LE ,  Gerald LELAIS ,  Yong JIA

IPC: A61K31/55 ,  A61P35/00

Abstract: Methods for the treatment of EGFR mutated cancer. For example, treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations (e.g., L858R and ex19del), the acquired or resistant “gatekeeper” T790M mutation, or any combination of these mutations.

公开(公告)号：US20210155713A1

公开(公告)日：2021-05-27

申请号：US17058870

申请日：2019-05-29

Applicant: Novartis AG

Inventor： Michael DIDONATO ,  Christoph ERKEL ,  Anna Galkin ,  Scott GLASER ,  Klaus Felix HARTLEPP ,  Yong JIA ,  Alexandra KRAUS ,  Christian Cho-Hua LEE ,  Sarah Michelle RUE ,  Jian SHI ,  Xenia Karola WEZLER

IPC: C07K16/40 ,  A61P35/00 ,  C07K16/28 ,  A61K39/395 ,  A61K45/06

Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.

公开(公告)号：US20180117059A1

公开(公告)日：2018-05-03

申请号：US15574347

申请日：2016-05-12

Applicant: Novartis AG

Inventor： NgocDiep LE ,  Gerald LELAIS ,  Yong JIA

IPC: A61K31/55 ,  A61P35/00

CPC classification number: A61K31/55 ,  A61P35/00

Abstract: Methods for the treatment of EGFR mutated cancer. For example, treatment of non-small cell lung cancer (NSCLC) with activating EGFR mutations (e.g., L858R and ex19del) the acquired or resistant “gatekeeper” T790M mutation, or any combination of these mutations.